Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, commonly known as Vertex, is a leading biotechnology company headquartered in the United States. Founded in 1989, Vertex has established itself as a pioneer in the development of transformative therapies for serious diseases, particularly in the field of cystic fibrosis. With major operational regions across North America and Europe, the company focuses on innovative drug discovery and development.
Vertex is renowned for its unique portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, and Trikafta, which have significantly improved the quality of life for patients. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as the first approved therapy for the underlying cause of cystic fibrosis. Vertex continues to drive advancements in biotechnology, solidifying its reputation as a key player in the industry.
+6 vs industry average
Vertex Pharmaceuticals’s score of 44 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Vertex Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Vertex Pharmaceuticals's reported carbon emissions
In 2025, Vertex Pharmaceuticals reported total carbon emissions of approximately 579,649,000 kg CO2e, comprising 12,296,000 kg CO2e from Scope 1, 1,278,000 kg CO2e from Scope 2 (market-based), and 579,649,000 kg CO2e from Scope 3 emissions. This data reflects a commitment to transparency in their environmental impact. Vertex has set ambitious reduction targets, aiming to decrease Scope 1 and 2 greenhouse gas emissions by 42% by 2032, using 2022 as the baseline year. This goal aligns with the Science Based Targets initiative (SBTi), demonstrating their commitment to climate action. The company has consistently reported emissions data, with previous years showing a total of approximately 551,647,000 kg CO2e in 2024 and 474,129,000 kg CO2e in 2023. These figures indicate a proactive approach to managing and reducing their carbon footprint. Vertex Pharmaceuticals, headquartered in the US, is dedicated to addressing climate change through measurable targets and transparent reporting, reinforcing its role in the biopharmaceutical industry’s shift towards sustainability.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Vertex Pharmaceuticals’s Climate Goals (2030 & 2050)
2 goals2032
42% reduction in Scope 2
Our current goal is to
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Vertex Pharmaceuticals
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project